A trial supports the use of the calcineurin-inhibitor tacrolimus as a targeted treatment for uremic pruritus and introduces IL-13 inhibition as a viable mechanism to address cytokine-mediated itch. Tacrolimus, sold under the brand name Prograf among others, is an immunosuppressive drug. After an allogenic organ transplant, the risk of organ rejection is moderate; tacrolimus is used to lower the risk of organ rejection.
When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ. Tacrolimus works by suppressing the immune system to prevent the white blood cells from trying to get rid of the transplanted organ. Tacrolimus is a very strong medicine. Tacrolimus is used together with other medicines in people who have had a heart, kidney, liver, or lung transplant.
tacrolimus moa, Tacrolimus weakens your immune system to prevent your body from "rejecting" the transplanted organ. Topical tacrolimus is commonly used for short-term treatment of moderate to severe atopic dermatitis, which is a type of eczema, in some people who do not have a weakened immune system. Topical... Tacrolimus (Astagraf XL, Envarsus XR, Prograf) is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received a kidney transplant. Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection.
tacrolimus moa, Tacrolimus is a prescription medication indicated for preventing organ rejection in heart, kidney, liver, or lung transplants.
